Documentos de Fricke-Galindo I. | REDI

Regresar

Mostrando 5 resultados de: 5

Filtros aplicados

Área temáticas: "Enfermedades"

Subtipo de publicación

Publisher

Pharmacogenomics(2)

Pharmacogenomics Journal(2)

Drug Metabolism and Personalized Therapy(1)

Área temáticas

Farmacología y terapéutica(4)

Medicina y salud(3)

Ginecología, obstetricia, pediatría, geriatría(1)

Ingeniería química(1)

Área de conocimiento

Farmacología(3)

Año de Publicación

Origen

Palabras Claves

pharmacogenetics(3)

CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy

Abstract: We aimed to explore the possible influence of CYP2C9 (∗2, ∗3 and IVS8-109 A>T), CYP2C19 (∗2, ∗3 and

Palabras claves:

Adrián LLerena, Dorado P., Familiar-López I., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.

Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers

Abstract: Aim: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy i

Palabras claves:

ABCC2, anti-epileptics, CYP3A5, EPHX1, GABRA1, HNF4A, Mexican-Mestizo, NR1I2, pharmacogenetics, RALBP1, SCN1A, SCN2A, UGT1A1, UGT2B7

Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.

Influence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy

Abstract: Genetic and nongenetic factors may contribute to lamotrigine (LTG) plasma concentration variability

Palabras claves:

Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.

Interethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: A report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics)

Abstract: Mexico presents a complex population diversity integrated by Mexican indigenous (MI) (7% of Mexico's

Palabras claves:

drug metabolizing enzymes, drug receptors, drug transporters, Mexicans, pharmacogenetics

Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.

Relevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital

Abstract: Aim: We evaluated the potential influence of genetic (CYP3A5, EPHX1, NR1I2, HNF4A, ABCC2, RALBP1, SC

Palabras claves:

ABCC2, carbamazepine, EPHX1, Epilepsy, NR1I2, pharmacogenetics

Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.